Antiangiogenic Therapy for Patients with Recurrent and Newly Diagnosed Malignant Gliomas

Abstract EN

Malignant gliomas have a poor prognosis despite advances in diagnosis and therapy.

Although postoperative temozolomide and radiotherapy improve overall survival in glioblastoma patients, most patients experience a recurrence.

The prognosis of recurrent malignant gliomas is dismal, and more effective therapeutic strategies are clearly needed.

Antiangiogenesis is currently considered an attractive targeting therapy for malignant gliomas due to its important role in tumor growth.

Clinical trials using bevacizumab have been performed for recurrent glioblastoma, and these studies have shown promising response rates along with progression-free survival.

Based on the encouraging results, bevacizumab was approved by the FDA for the treatment of recurrent glioblastoma.

In addition, bevacizumab has shown to be effective for recurrent anaplastic gliomas.

Large phase III studies are currently ongoing to demonstrate the efficacy and safety of the addition of bevacizumab to temozolomide and radiotherapy for newly diagnosed glioblastoma.

In contrast, several other antiangiogenic drugs have also been used in clinical trials.

However, previous studies have not shown whether antiangiogenesis improves the overall survival of malignant gliomas.

Specific severe side effects, difficult assessment of response, and lack of rational predictive markers are challenging problems.

Further studies are warranted to establish the optimized antiangiogenesis therapy for malignant gliomas.